Group 1: China Construction - The total new contracts signed by China Construction from January to October reached 3.61 trillion yuan, representing a year-on-year increase of 1% [1] Group 2: Changyuan Power - Changyuan Power's subsidiary received approval for the 100MW wind power project in Songzi, Hubei [2] Group 3: China Metallurgical Group - China Metallurgical Group reported a total new contract amount of 845.07 billion yuan from January to October, a decrease of 11.8% year-on-year, while overseas contracts increased by 7.3% to 71.16 billion yuan [4] Group 4: Shapuaisi - Shapuaisi received approval for clinical trials of deoxycorticosterone ketone solution, intended for use during cataract surgery [5] Group 5: Jianfeng Group - Jianfeng Group's subsidiary received approval for clinical trials of a new drug for treating advanced non-squamous non-small cell lung cancer [7] Group 6: Chongqing Steel - Chongqing Steel announced the resignation of its president Meng Wenwang due to work adjustments [8] Group 7: Tianma Technology - Tianma Technology reported an output of approximately 1732.99 tons of eel in October, with a total output of about 15218.73 tons from January to October [10] Group 8: Qingyuan Co. - Qingyuan Co.'s controlling shareholder reduced holdings of convertible bonds by 685,400 units, accounting for 13.71% of the total issuance [11] Group 9: Spring Airlines - Spring Airlines reported a passenger turnover of 506,200.49 million kilometers in October, a year-on-year increase of 20.06% [12] Group 10: China Merchants Port - China Merchants Port reported a total container volume of 17.1714 million TEUs from January to October, a year-on-year increase of 5.1% [13] Group 11: Yangdian Technology - Yangdian Technology announced a change in control following a share transfer [15] Group 12: Wanfu Biology - Wanfu Biology decided to postpone the implementation of its Knowledge City production base project [16] Group 13: Iwu Biology - Iwu Biology terminated the research project for a specific drug, which will reduce its 2025 net profit by approximately 333.79 million yuan [17] Group 14: Hainan Rubber - Hainan Rubber received an insurance payout of 22.9241 million yuan due to revenue loss from rubber price fluctuations [19] Group 15: Xinjiang Tianye - Xinjiang Tianye plans to establish a joint venture with Tianchi Energy to develop coal chemical projects [20] Group 16: China Coal Energy - China Coal Energy's executive director and president Zhao Rongzhe resigned due to reaching retirement age [22] Group 17: Huading Co. - Huading Co. received approval for a stock issuance to specific investors from the Shanghai Stock Exchange [24] Group 18: Zhongmu Co. - Zhongmu Co. decided to waive its right of first refusal for a 4.04% stake in a subsidiary [25] Group 19: Tianlong Co. - Tianlong Co. reported that its subsidiary's stock issuance was approved by the Beijing Stock Exchange [26] Group 20: Hualan Co. - Hualan Co.'s subsidiary plans to invest 20 million yuan in a biotechnology company [27] Group 21: Haichen Pharmaceutical - Haichen Pharmaceutical received a drug registration certificate for a new injection [28] Group 22: Aier Eye Hospital - Aier Eye Hospital plans to invest 300 million yuan in wealth management products [29] Group 23: Xiamen Engineering Machinery - Xiamen Engineering Machinery announced a planned share reduction by a major shareholder [30] Group 24: Guotai Group - Guotai Group successfully acquired 100% of a mining technology company for 110.1 million yuan [31] Group 25: Wanfeng Aowei - Wanfeng Aowei reached a settlement regarding an arbitration matter with a subsidiary [32] Group 26: Taihe Technology - Taihe Technology is undergoing technical upgrades for its ethylene carbonate project [33] Group 27: Renhe Pharmaceutical - Renhe Pharmaceutical's controlling shareholder plans to reduce holdings by 0.21% [34] Group 28: Changshu Bank - Changshu Bank's second-largest shareholder increased its stake to 3.98% [35] Group 29: Overseas Chinese Town A - Overseas Chinese Town A reported a 57% decrease in contract sales in October [36] Group 30: Canadian Solar - Canadian Solar's controlling shareholder expects total revenue of 1.3 to 1.5 billion USD in Q4 2025 [38] Group 31: Zhonggong Education - Zhonggong Education's controlling shareholder's shares will be auctioned due to a loan dispute [40] Group 32: Aikexibo - Aikexibo's shareholders plan to reduce their holdings by up to 3% [42] Group 33: Wanhua Chemical - Wanhua Chemical's shareholder plans to reduce holdings by up to 0.5% [44] Group 34: Jujie Microfiber - Jujie Microfiber's controlling shareholder plans to reduce holdings by up to 2% [45] Group 35: Wangsu Technology - Wangsu Technology's shareholder plans to reduce holdings by up to 1% [46] Group 36: Tianli Lithium Energy - Tianli Lithium Energy received a patent for lithium-ion battery materials [47] Group 37: Heshun Electric - Heshun Electric won a 40 million yuan project for energy storage services [49] Group 38: Changchun High-tech - Changchun High-tech's subsidiary received FDA approval for a clinical trial of a new drug [51] Group 39: Dongrui Co. - Dongrui Co. received an additional export quota for live pigs to Hong Kong [52] Group 40: Zhongwei Co. - Zhongwei Co. set the H-share issuance price at 34 HKD per share [53] Group 41: Fospower Technology - Fospower Technology plans to invest in a lithium sulfide project with partners [54]

临床试验批准通知书的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 近日，浙江莎普爱思药业股份有限公司（以下简称"公司"）获得国家药品 监督管理局核准签发的关于去氧肾上腺素酮咯酸溶液的《药物临床试验批准通知 书》（通知书编号：2025LP03018），公司拟于条件具备后开展临床试验。现将 相关情况公告如下： 证券代码：603168 证券简称：莎普爱思 公告编号：临 2025-068 浙江莎普爱思药业股份有限公司 关于获得去氧肾上腺素酮咯酸溶液 申请事项：临床试验 审批结论：根据《中华人民共和国药品管理法》及有关规定，经审查，同意 开展临床试验。 二、药物的其他情况 本品主要适用于白内障手术或人工晶状体置换手术过程中维持散瞳，防止手 术中瞳孔缩小并且缓解术后眼部疼痛。 截至本公告披露日，去氧肾上腺素酮咯酸溶液项目累计研发投入约555.63万 元人民币。 三、风险提示 一、药物的基本情况 药品名称：去氧肾上腺素酮咯酸溶液 剂型：眼用制剂 注册分类：化学药品3类 申请人：浙江莎普爱思药业股份有限公司 根据我国药品注册相关的法律 ...

Core Viewpoint - The company, Shapais (603168.SH), has received approval from the National Medical Products Administration for clinical trials of a new drug, deoxymidodrine ketorolac solution, aimed at maintaining pupil dilation during cataract surgery and alleviating postoperative eye pain [1] Group 1 - The drug is specifically indicated for use during cataract surgery or artificial lens replacement procedures [1] - The company plans to initiate clinical trials once conditions are met [1] - Cumulative research and development investment in the deoxymidodrine ketorolac solution project has reached approximately 5.5563 million RMB [1]

Core Viewpoint - The company, Shapuaisi (603168.SH), has received approval from the National Medical Products Administration for clinical trials of deoxycorticosterone ketone acid solution, which is intended for use during cataract surgery to maintain pupil dilation and alleviate postoperative eye pain [1] Group 1 - The company plans to conduct clinical trials once conditions are met [1] - The drug is primarily used to prevent pupil constriction during cataract surgery or artificial lens replacement [1] - As of the announcement date, the total R&D investment in the deoxycorticosterone ketone acid solution project is approximately 5.5563 million RMB [1]

Core Viewpoint - The company, Shapais (603168.SH), has received approval from the National Medical Products Administration for a clinical trial of deoxycorticosterone ketone solution, indicating a significant step in its product development pipeline [1] Group 1: Clinical Trial Approval - The company has obtained the clinical trial approval notice (No. 2025LP03018) for deoxycorticosterone ketone solution [1] - The clinical trial is planned to be conducted once conditions are met [1] Group 2: Product Application - The product is primarily intended for use during cataract surgery or artificial lens replacement surgery to maintain pupil dilation, prevent pupil constriction during surgery, and alleviate postoperative eye pain [1]

Core Viewpoint - The company has received approval from the National Medical Products Administration for clinical trials of a new ophthalmic drug, deoxymidodrine ketorolac solution, aimed at maintaining pupil dilation during cataract surgery and alleviating postoperative eye pain [1] Group 1: Company Developments - The drug is specifically designed for use during cataract surgery or artificial lens replacement procedures [1] - The company plans to initiate clinical trials once conditions are met [1] - Cumulative research and development investment in the project has reached approximately 5.56 million RMB [1]

Core Viewpoint - The company has received approval from the National Medical Products Administration for a clinical trial of a new drug, which is aimed at maintaining pupil dilation during cataract surgery and alleviating postoperative eye pain [1] Group 1 - The drug in question is deoxycorticosterone ketone solution, which is specifically indicated for use during cataract surgery or artificial lens replacement [1] - The approval is significant as it allows the company to proceed with clinical trials, potentially leading to a new product in the ophthalmology market [1]

Core Viewpoint - Zhejiang Shapuaisi Pharmaceutical Co., Ltd. is convening its second extraordinary general meeting of shareholders in 2025 on November 19, 2025, to discuss various proposals including amendments to the company's articles of association [2][3]. Meeting Details - The meeting type is the second extraordinary general meeting of shareholders in 2025 [3]. - The meeting will be convened by the board of directors [3]. - Voting will be conducted through a combination of on-site and online methods [3]. - The meeting is scheduled for November 19, 2025, at 10:00 AM, located at the company's office building in Pinghu City, Zhejiang Province [3]. - Online voting will be available on the Shanghai Stock Exchange's shareholder meeting network voting system from 9:15 AM to 3:00 PM on the same day [4]. Voting Procedures - Shareholders can vote via the Shanghai Stock Exchange network voting system, with specific time slots for trading system voting and internet platform voting [4][5]. - Shareholders holding multiple accounts can aggregate their voting rights across all accounts [6]. - Duplicate voting through different methods will be counted based on the first vote cast [6]. Attendance and Registration - Shareholders registered with the China Securities Depository and Clearing Corporation Limited are entitled to attend the meeting [8]. - Registration for attendance requires specific documentation depending on whether the shareholder is a legal entity or an individual [9][10]. - Registration will take place on November 18, 2025, from 9:00 AM to 4:30 PM [10]. Other Information - The meeting is expected to last half a day, and attendees will bear their own travel and accommodation costs [11]. - Attendees must report to the meeting location by 10:00 AM on November 19, 2025 [12].

证券代码：603168 证券简称：莎普爱思 公告编号：临 2025-067 浙江莎普爱思药业股份有限公司 关于召开 2025 年第二次临时股东会的提示性公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： (五)网络投票的系统、起止日期和投票时间。 网络投票系统：上海证券交易所股东会网络投票系统 浙江莎普爱思药业股份有限公司（以下简称"公司"）于2025年10月30日召 开的第六届董事会第十一次会议审议通过了《关于豁免第六届董事会第十一次会 议通知期限的议案》、《关于2025年第三季度报告的议案》等议案，其中《关于 修订<公司章程>的议案》需提交公司2025年第二次临时股东会审议，详细内容请 见公司于2025年10月31日在《中国证券报》、《上海证券报》、《证券时报》、 《证券日报》和上海证券交易所网站（www.sse.com.cn）上披露的公告。 为确保公司股东充分了解本次股东会的相关信息，现将相关事项提示公告如 下： 一、 召开会议的基本情况 (一)股东会类型和届次：2025 年第二次临时股东会 (二)股东 ...

浙江莎普爱思药业股份有限公司 2025 年第二次临时股东会会议资料 浙江莎普爱思药业股份有限公司 2025 年第二次临时股东会 会 议 资 料 二〇二五年十一月十九日 1 浙江莎普爱思药业股份有限公司 2025 年第二次临时股东会会议资料 目 录 | 2025 年第二次临时股东会会议须知 | 3 | | --- | --- | | 2025 年第二次临时股东会会议议程 | 5 | | 2025 年第二次临时股东会会议议案 | 6 | | 议案一：关于修订《公司章程》的议案 | 6 | 2 浙江莎普爱思药业股份有限公司 2025 年第二次临时股东会会议资料 浙江莎普爱思药业股份有限公司 2025 年第二次临时股东会会议须知 为了维护全体股东的合法权益，确保股东会的正常秩序和议事效率，保证大会 的顺利进行，根据《公司章程》、公司《股东会议事规则》等相关法律法规的要求， 特制定 2025 年第二次临时股东会会议须知。 浙江莎普爱思药业股份有限公司 2025 年第二次临时股东会会议资料 七、本次股东会由公司聘请的北京市金杜律师事务所律师现场见证并出具法律 意见书。 八、股东出席本次股东会所产生的费用由股东自行承担。公 ...